$TNDM
TANDEM DIABETES CARE INC Stock $tndm

$tndm Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-K Financial Statement

#000156459015000886 Filed on February 24, 2015

Income Statement

Concept	2015 Q1	2014 Q4	2013 Q4
Revenue	$12.31M	$17.89M	$10.25M
YoY Change	52.59%	74.61%	345.43%
Cost Of Revenue	$9.500M	$11.40M	$9.100M
YoY Change	31.96%	25.27%	237.04%
Gross Profit	$2.808M	$6.537M	$1.188M
YoY Change	223.88%	450.25%	-397.0%
Gross Profit Margin	22.81%	36.54%	11.6%
Selling, General & Admin	$19.36M	$20.10M	$14.30M
YoY Change	7.28%	40.56%	138.33%
% of Gross Profit	689.28%	307.48%	1203.7%
Research & Development	$3.863M	$3.900M	$3.300M
YoY Change	5.46%	18.18%	65.0%
% of Gross Profit	137.57%	59.66%	277.78%
Depreciation & Amortization	$1.182M	$1.310M	$710.0K
YoY Change	28.34%	84.51%	-4.05%
% of Gross Profit	42.09%	20.04%	59.76%
Operating Expenses	$23.22M	$24.04M	$17.65M
YoY Change	6.98%	36.19%	120.64%
Operating Profit	-$20.41M	-$17.50M	-$16.46M
YoY Change	-2.05%	6.31%	95.99%
Interest Expense	-$800.0K	-$900.0K	-$7.200M
YoY Change	-27.27%	-87.5%	3500.0%
% of Operating Profit
Other Income/Expense, Net	-$798.0K
YoY Change	-29.0%
Pretax Income	-$21.20M	-$18.40M	-$23.60M
YoY Change	-3.64%	-22.03%	174.42%
Income Tax		$100.0K	$0.00
% Of Pretax Income
Net Earnings	-$21.21M	-$18.47M	-$23.61M
YoY Change	-3.43%	-21.8%	174.58%
Net Earnings / Revenue	-172.31%	-103.22%	-230.49%
Basic Earnings Per Share
Diluted Earnings Per Share	-$7.310M	-$7.708M	-$10.26M
COMMON SHARES
Basic Shares Outstanding	23.71M
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014 Q4	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$116.4M	$67.30M	$129.5M
YoY Change	5.05%	-48.03%	652.91%
Cash & Equivalents	$62.55M	$31.18M	$124.4M
Short-Term Investments	$53.80M	$36.10M	$5.100M
Other Short-Term Assets	$4.000M	$3.900M	$3.900M
YoY Change	0.0%	0.0%	95.0%
Inventory	$13.58M	$11.91M	$10.33M
Prepaid Expenses
Receivables	$5.226M	$7.652M	$5.299M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$139.2M	$90.75M	$149.0M
YoY Change	8.41%	-39.09%	435.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.93M	$12.58M	$9.886M
YoY Change	19.55%	27.26%	9.84%
Goodwill
YoY Change
Intangibles			$2.697M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$692.0K	$691.0K	$643.0K
YoY Change	15.69%	7.47%
Total Long-Term Assets	$15.98M	$15.71M	$13.23M
YoY Change	13.87%	18.8%	10.22%
TOTAL ASSETS
Total Short-Term Assets	$139.2M	$90.75M	$149.0M
Total Long-Term Assets	$15.98M	$15.71M	$13.23M
Total Assets	$155.1M	$106.5M	$162.2M
YoY Change	8.94%	-34.37%	307.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.087M	$1.949M	$2.352M
YoY Change	99.04%	-17.13%	38.35%
Accrued Expenses	$2.586M	$2.920M	$1.874M
YoY Change	73.71%	55.82%	-46.46%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$18.77M	$18.09M	$14.60M
YoY Change	42.89%	23.94%	-14.63%
LONG-TERM LIABILITIES
Long-Term Debt	$29.50M	$30.00M	$29.40M
YoY Change	0.34%	2.04%
Other Long-Term Liabilities	$2.102M	$1.658M	$795.0K
YoY Change	188.45%	108.55%	-81.07%
Total Long-Term Liabilities	$2.102M	$31.66M	$795.0K
YoY Change	188.45%	3882.14%	-81.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.77M	$18.09M	$14.60M
Total Long-Term Liabilities	$2.102M	$31.66M	$795.0K
Total Liabilities	$52.88M	$51.89M	$46.68M
YoY Change	17.17%	11.17%	120.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$269.9M	-$248.7M	-$169.2M
YoY Change	41.21%	47.0%
Common Stock	$372.1M	$303.3M	$23.00K
YoY Change	1619414.32%	1318504.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$102.2M	$54.57M	$115.5M
YoY Change
Total Liabilities & Shareholders Equity	$155.1M	$106.5M	$162.2M
YoY Change	8.94%	-34.37%	307.58%

Cashflow Statement

Concept	2015 Q1	2014 Q4	2013 Q4
OPERATING ACTIVITIES
Net Income	-$21.21M	-$18.47M	-$23.61M
YoY Change	-3.43%	-21.8%	174.58%
Depreciation, Depletion And Amortization	$1.182M	$1.310M	$710.0K
YoY Change	28.34%	84.51%	-4.05%
Cash From Operating Activities	-$15.42M	-$15.14M	-$12.83M
YoY Change	-9.08%	18.0%	29.73%
INVESTING ACTIVITIES
Capital Expenditures	$600.0K	$850.0K	-$1.480M
YoY Change	-62.96%	-157.43%	74.12%
Acquisitions
YoY Change
Other Investing Activities	-$17.67M	$8.260M	-$5.100M
YoY Change	-39.09%	-261.96%
Cash From Investing Activities	-$18.27M	$9.110M	-$6.580M
YoY Change	-40.35%	-238.45%	674.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$217.0K
YoY Change	711.25%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	65.07M	1.650M	128.2M
YoY Change	243161.43%	-98.71%	532.61%
NET CHANGE
Cash From Operating Activities	-15.42M	-15.14M	-12.83M
Cash From Investing Activities	-18.27M	9.110M	-6.580M
Cash From Financing Activities	65.07M	1.650M	128.2M
Net Change In Cash	31.38M	-4.380M	108.8M
YoY Change	-165.98%	-104.02%	1041.87%
FREE CASH FLOW
Cash From Operating Activities	-$15.42M	-$15.14M	-$12.83M
Capital Expenditures	$600.0K	$850.0K	-$1.480M
Free Cash Flow	-$16.02M	-$15.99M	-$11.35M
YoY Change	-13.78%	40.88%	25.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2013Q4	us-gaap	Inventory Net InventoryNet	10330000
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	643000
CY2014Q4	us-gaap	Assets Assets	106464000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1949000
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2920000
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	29440000
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	303255000
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1912000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1422000
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	779000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	476000
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	349000
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18094000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31176000
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4086000
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2700000
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1658000
CY2014Q4	us-gaap	Liabilities Liabilities	51892000
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2663000
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23714990
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Entity Registrant Name EntityRegistrantName	TANDEM DIABETES CARE INC
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001438133
CY2014	dei	Trading Symbol TradingSymbol	TNDM
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3789000
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	188000
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-21.46
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.42
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1874000
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1830000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	124385000
CY2014Q2	dei	Entity Public Float EntityPublicFloat	180000000
CY2014Q4	us-gaap	Inventory Net InventoryNet	11913000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2000000
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5299000
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7652000
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9722000
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2050000
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5876000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	90751000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	148989000
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	5095000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12581000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1904000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9886000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	691000
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	36106000
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2942000
CY2013Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1737000
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23821000
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17466000
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11240000
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7580000
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1887000
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	840000
CY2013Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	29397000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	24000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	54572000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	106464000
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	795000
CY2013Q4	us-gaap	Liabilities Liabilities	46678000
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-248715000
CY2013	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	9002000
CY2012	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2556000
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13705000
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-79524000
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63139000
CY2014	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	8000
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-79516000
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33015000
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-175.88
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	23000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	162215000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-169191000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	115537000
CY2013Q4	us-gaap	Assets Assets	162215000
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2352000
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	411000
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14599000
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8000
CY2014	us-gaap	Interest And Other Income InterestAndOtherIncome	112000
CY2013	us-gaap	Interest And Other Income InterestAndOtherIncome	7000
CY2012	us-gaap	Interest And Other Income InterestAndOtherIncome	2000
CY2014	us-gaap	Interest Expense Other InterestExpenseOther	3901000
CY2013	us-gaap	Interest Expense Other InterestExpenseOther	4710000
CY2012	us-gaap	Interest Expense Other InterestExpenseOther	2525000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79453000
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63139000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33015000
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	71000
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-63139000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-33015000
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	248000
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	35000
CY2012	tndm	Conversion Of Series A Series B And Series C Preferred Stock To Common Stock Amount ConversionOfSeriesASeriesBAndSeriesCPreferredStockToCommonStockAmount	550000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	246000
CY2012	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	50000
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	284705000
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23655000
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23655000
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22926000
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22926000
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	49722000
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	29007000
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	2475000
CY2014	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	34474000
CY2013	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	22840000
CY2012	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3823000
CY2014	us-gaap	Gross Profit GrossProfit	15248000
CY2013	us-gaap	Gross Profit GrossProfit	6167000
CY2012	us-gaap	Gross Profit GrossProfit	-1348000
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	75121000
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44522000
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22691000
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15791000
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11079000
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9009000
CY2014	us-gaap	Operating Expenses OperatingExpenses	90912000
CY2013	us-gaap	Operating Expenses OperatingExpenses	55601000
CY2012	us-gaap	Operating Expenses OperatingExpenses	31700000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-75664000
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-49434000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-33048000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-71295000
CY2013	tndm	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-522000
CY2012	tndm	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-234000
CY2014	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	810000
CY2014	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-1575000
CY2013	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	895000
CY2012	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2342000
CY2014	tndm	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-461000
CY2013	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	763000
CY2013	us-gaap	Increase Decrease In Due To Employees Current IncreaseDecreaseInDueToEmployeesCurrent	25000
CY2012	tndm	Loss On Extinguishment Of Liabilities On Conversion Of Convertible Notes Payable LossOnExtinguishmentOfLiabilitiesOnConversionOfConvertibleNotesPayable	2771000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-106052000
CY2013	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	437000
CY2013	tndm	Issuance Of Common Stock Initial Public Offering Net Of Underwriting Discounts And Commissions IssuanceOfCommonStockInitialPublicOfferingNetOfUnderwritingDiscountsAndCommissions	125039000
CY2013	tndm	Conversion Of Preferred Stock To Common Stock In Connection With Initial Public Offering Value ConversionOfPreferredStockToCommonStockInConnectionWithInitialPublicOfferingValue	144258000
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	33000
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	9550000
CY2013	tndm	Stock Issued During Period Value Common Stock Warrants Exercised StockIssuedDuringPeriodValueCommonStockWarrantsExercised	628000
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	66000
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4717000
CY2014	tndm	Stock Issued During Period Value Common Stock Warrants Exercised StockIssuedDuringPeriodValueCommonStockWarrantsExercised	138000
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	325000
CY2014	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3168000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14920000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4389000
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3167000
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2032000
CY2012	us-gaap	Accretion Of Discount AccretionOfDiscount	1209000
CY2014	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	219000
CY2013	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	595000
CY2012	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	836000
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	188000
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	275000
CY2012	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	46000
CY2014	us-gaap	Inventory Write Down InventoryWriteDown	163000
CY2013	us-gaap	Inventory Write Down InventoryWriteDown	815000
CY2012	us-gaap	Inventory Write Down InventoryWriteDown	335000
CY2014	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	53000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	14995000
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	4456000
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	246000
CY2014	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	41000
CY2013	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	62000
CY2012	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	57000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2541000
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3161000
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2458000
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1820000
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4625000
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6596000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	82000
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-106000
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1054000
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	150000
CY2013	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	85000
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1225000
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	859000
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1383000
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	973000
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	342000
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	918000
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3846000
CY2013	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3885000
CY2012	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	979000
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	429000
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1472000
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1884000
CY2012	us-gaap	Increase Decrease In Due To Employees Current IncreaseDecreaseInDueToEmployeesCurrent	175000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-61378000
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	71000
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	19000
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	30000000
CY2013	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4396000
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	3000
CY2012	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	604000
CY2013	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	15991000
CY2012	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	30867000
CY2013	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	125040000
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3664000
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2575000
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	35000
CY2012	us-gaap	Interest Paid InterestPaid	297000
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-47757000
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-33471000
CY2014	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	67101000
CY2013	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	5095000
CY2014	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	36210000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4406000
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4010000
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4529000
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	173000
CY2013	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000000
CY2012	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1000000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-35470000
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-11105000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5529000
CY2012	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	12208000
CY2014	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	29925000
CY2013	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	28874000
CY2012	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5000000
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-50000
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	2000000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3639000
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	166084000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	47506000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-93209000
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	107222000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8506000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17163000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8657000
CY2014	us-gaap	Interest Paid InterestPaid	3369000
CY2013	us-gaap	Interest Paid InterestPaid	4115000
CY2014	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	1604000
CY2012	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	2018000
CY2012	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2770000
CY2013	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	437000
CY2012	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	3815000
CY2014	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	789000
CY2012	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	200000
CY2014	tndm	Patent Acquisition Costs Included In Accrued Expenses PatentAcquisitionCostsIncludedInAccruedExpenses	74000
CY2013	tndm	Conversion Of Preferred Stock Warrants To Common Stock Warrants ConversionOfPreferredStockWarrantsToCommonStockWarrants	9550000
CY2013	tndm	Conversion Of Convertible Preferred Stock Into Common Stock ConversionOfConvertiblePreferredStockIntoCommonStock	144258000
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4100000
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2800000
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1900000
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes as of the date of the financial statements. Actual results could differ from those estimates and assumptions. </p></div>
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company maintains deposit accounts in federally insured financial institutions in excess of federally insured limits. The Company also maintains investments in money market funds that are not federally insured. Additionally, the Company has established guidelines regarding investment instruments and their maturities, which are designed to maintain preservation of principal and liquidity.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes customers who accounted for 10% or more of net accounts receivable: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" style="width:70%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;"> </p></td> <td valign="bottom" style="width:1%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;"> </p></td> <td colspan="6" valign="top" style="width:1%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td valign="bottom" style="width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"> </p></td> </tr> <tr> <td valign="bottom" style="width:70%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;"> </p></td> <td valign="bottom" style="width:1%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;"> </p></td> <td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 1pt #000000;"> <p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">2014</p></td> <td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;"> </p></td> <td valign="top" style="width:1%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"> </p></td> <td colspan="2" valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 1pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td> <td valign="bottom" style="width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"> </p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Byram Healthcare</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:12%;"> <p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">19.2</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">%</p></td> <td valign="top" bgcolor="#CFF0FC" style="width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:12%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> </tr> <tr> <td valign="bottom" style="width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edgepark Medical Supplies, Inc.</p></td> <td valign="bottom" style="width:1%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"> </p></td> <td valign="bottom" style="width:1%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"> </p></td> <td valign="bottom" style="width:12%;"> <p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">12.3</p></td> <td valign="bottom" style="width:1%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">%</p></td> <td valign="top" style="width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td valign="bottom" style="width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td valign="bottom" style="width:12%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1</p></td> <td valign="bottom" style="width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="width:70%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CCS Medical, Inc.</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:12%;"> <p style="text-align:right;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-weight:normal;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">N/A</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"> <p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"> </p></td> <td valign="top" bgcolor="#CFF0FC" style="width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:12%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.4</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes customers who accounted for 10% or more of sales for the periods presented: </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2012</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edgepark Medical Supplies, Inc.</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.0</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.1</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.3</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CCS Medical, Inc.</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.6</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.6</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Byram Healthcare</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Solara Medical Supplies, Inc.</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.7</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p></div>
CY2012Q3	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	5000000
CY2012Q3	tndm	Patent Related To Commercialized Products PatentRelatedToCommercializedProducts	3200000
CY2012Q3	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P10Y
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1800000
CY2014Q4	tndm	Weighted Average Remaining Amortization Period WeightedAverageRemainingAmortizationPeriod	90000
CY2013Q4	tndm	Weighted Average Remaining Amortization Period WeightedAverageRemainingAmortizationPeriod	102000
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	176000
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1151000
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	300000
CY2014Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	66156000
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	58000
CY2013Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	120207000
CY2014Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2013Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2013Q4	us-gaap	Line Of Credit LineOfCredit	0
CY2014Q4	us-gaap	Line Of Credit LineOfCredit	0
CY2013Q1	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2015-01-31
CY2014Q4	tndm	Future Minimum Annual Revenues Attainable In Next Twelve Months FutureMinimumAnnualRevenuesAttainableInNextTwelveMonths	30000000
CY2014Q4	tndm	Future Minimum Annual Revenues Attainable In Second Year FutureMinimumAnnualRevenuesAttainableInSecondYear	50000000
CY2014Q4	tndm	Future Minimum Annual Revenues Attainable In Third Year FutureMinimumAnnualRevenuesAttainableInThirdYear	65000000
CY2014Q4	tndm	Future Minimum Annual Revenues Attainable In Fourth Year FutureMinimumAnnualRevenuesAttainableInFourthYear	80000000
CY2014Q4	tndm	Future Minimum Annual Revenues Attainable Thereafter FutureMinimumAnnualRevenuesAttainableThereafter	95000000
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	11250000
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	15000000
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	3750000
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	30000000
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	30000000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	135902
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4430214
CY2014	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2006-01-27
CY2014	us-gaap	Restructuring And Related Activities Completion Date RestructuringAndRelatedActivitiesCompletionDate	2008-01-07
CY2014	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-1.6756
CY2014Q1	us-gaap	Inventory Recall Expense InventoryRecallExpense	1700000
CY2013	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-510000
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000
CY2013Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1123000
CY2014	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	3709000
CY2014	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	2858000
CY2014Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1974000
CY2014Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	535000
CY2014Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	1439000
CY2012Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	300000
CY2013	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	3515000
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	9913
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	16587
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4539616
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	760639
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	143779
CY2014Q1	tndm	Product Replacement Related Costs ProductReplacementRelatedCosts	700000
CY2014Q1	us-gaap	Inventory Write Down InventoryWriteDown	1000000
CY2014	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2014Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	0
CY2013Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	0
CY2014	us-gaap	Threshold Period Past Due For Writeoff Of Trade Accounts Receivable ThresholdPeriodPastDueForWriteoffOfTradeAccountsReceivable	P120D
CY2012Q4	us-gaap	Deferred Revenue DeferredRevenue	1900000
CY2013Q4	us-gaap	Deferred Revenue DeferredRevenue	1900000
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1100000
CY2014	tndm	Revenue Recognition Period RevenueRecognitionPeriod	P4Y
CY2014	tndm	Offered Period For Sales Return Prior To Expiration OfferedPeriodForSalesReturnPriorToExpiration	P30D
CY2014Q4	tndm	Allowance For Sales Returns AllowanceForSalesReturns	300000
CY2013Q4	tndm	Allowance For Sales Returns AllowanceForSalesReturns	200000
CY2013	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	2182000
CY2013Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	549000
CY2013Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	574000
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2014	us-gaap	Advertising Expense AdvertisingExpense	1500000
CY2013	us-gaap	Advertising Expense AdvertisingExpense	700000
CY2012	us-gaap	Advertising Expense AdvertisingExpense	68000
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3368000
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6035000
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12095000
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	36040000
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9000
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	36048000
CY2014Q4	us-gaap	Trading Securities Equity Cost TradingSecuritiesEquityCost	36096000
CY2014Q4	tndm	Trading Securities Gross Unrealized Gain Accumulated In Investments TradingSecuritiesGrossUnrealizedGainAccumulatedInInvestments	11000
CY2014Q4	tndm	Trading Securities Gross Unrealized Loss Accumulated In Investments TradingSecuritiesGrossUnrealizedLossAccumulatedInInvestments	1000
CY2014Q4	us-gaap	Trading Securities TradingSecurities	36106000
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	5095000
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	5095000
CY2014Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	7905000
CY2013Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	5516000
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	253000
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	217000
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	7085000
CY2013Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6363000
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2288000
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2169000
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2856000
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3535000
CY2014Q4	us-gaap	Inventory Gross InventoryGross	12229000
CY2013Q4	us-gaap	Inventory Gross InventoryGross	12067000
CY2014Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	316000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	23385000
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	17590000
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14995000
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4456000
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	246000
CY2014	tndm	Capitalized Stock Based Compensation CapitalizedStockBasedCompensation	200000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	145413
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5011063
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4943856
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2322666
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.33
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.92
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.65
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.71
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.07
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	21.26
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.26
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	12.10
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.20
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.15
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.86
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y5M27D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M13D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M13D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y3M26D
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	118000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	80369000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1959000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23534000
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	141000
CY2013	tndm	Capitalized Stock Based Compensation CapitalizedStockBasedCompensation	300000
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	24700000
CY2014	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2014	us-gaap	Dividends Dividends	0
CY2014Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8537488
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	27065000
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	21467000
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	11225000
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	3912000
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2784000
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1793000
CY2013	tndm	Income Tax Reconciliation Nondeductible Convertible Notes Payable IncomeTaxReconciliationNondeductibleConvertibleNotesPayable	3000
CY2012	tndm	Income Tax Reconciliation Nondeductible Convertible Notes Payable IncomeTaxReconciliationNondeductibleConvertibleNotesPayable	617000
CY2013	tndm	Income Tax Reconciliation Warrants Revaluation IncomeTaxReconciliationWarrantsRevaluation	3061000
CY2012	tndm	Income Tax Reconciliation Warrants Revaluation IncomeTaxReconciliationWarrantsRevaluation	-869000
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	-646000
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	-649000
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	209000
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1973000
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	831000
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	82000
CY2014	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	355000
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-39000
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	73000
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29366000
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	21044000
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12906000
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	69600000
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	47996000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2934000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2349000
CY2014Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	10750000
CY2013Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7686000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	154000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	119000
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	6481000
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	2490000
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3272000
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3188000
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	93191000
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63828000
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	93191000
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63828000
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	177200000
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	190600000
CY2014	tndm	Deferred Tax Assets Tax Credit Carryforwards Research Expiration Start Year DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationStartYear	2028
CY2014	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The evaluation of uncertainty in a tax position is a two-step process. The first step involves recognition. The Company determines whether it is more likely than not that a tax position will be sustained upon tax examination, including resolution of any related appeals or litigation, based on only the technical merits of the position. The technical merits of a tax position derive from both statutory and judicial authority (legislation and statutes, legislative intent, regulations, rulings, and case law) and their applicability to the facts and circumstances of the tax position. If a tax position does not meet the more-likely-than-not recognition threshold, the benefit of that position is not recognized in the financial statements. The second step is measurement. A tax position that meets the more-likely-than-not recognition threshold is measured to determine the amount of benefit to recognize in the financial statements. The tax position is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate resolution with a taxing authority.
CY2013Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2014	tndm	Defined Contribution Plan Minimum Age Of Employee DefinedContributionPlanMinimumAgeOfEmployee	P18Y
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	467000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3539000
CY2014Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3000000
CY2014Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12127000
CY2013Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-16463000
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-11163000
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	14083000
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	14660000
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	17651000
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7167000
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13677000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-15301000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-13061000
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-23614000
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-53.77
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-60.96
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.14
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.78
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	5458000
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	5528000
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	7776000
CY2013Q4	us-gaap	Sales Revenue Net SalesRevenueNet	10245000
CY2013Q1	us-gaap	Gross Profit GrossProfit	2040000
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-72.50
CY2013Q2	us-gaap	Gross Profit GrossProfit	406000
CY2013Q3	us-gaap	Gross Profit GrossProfit	2533000
CY2013Q4	us-gaap	Gross Profit GrossProfit	1188000
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	9207000
CY2014Q4	tndm	Number Of Pending Legal Proceeding NumberOfPendingLegalProceeding	0
CY2013Q4	tndm	Number Of Pending Legal Proceeding NumberOfPendingLegalProceeding	0
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2555000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2815000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2924000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	3024000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1275000
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	12593000
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	8066000
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	10254000
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	13513000
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	17889000
CY2014Q1	us-gaap	Gross Profit GrossProfit	867000
CY2014Q2	us-gaap	Gross Profit GrossProfit	3448000
CY2014Q3	us-gaap	Gross Profit GrossProfit	4396000
CY2014Q4	us-gaap	Gross Profit GrossProfit	6537000
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	21704000
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	21766000
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	23403000
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	24039000
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-20837000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18318000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19007000
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-17502000
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-21961000
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-19197000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-19901000
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-18465000
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.96
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.83

Files In Submission

Name	View Source	Status
0001564590-15-000886-index-headers.html	Edgar Link	pending
0001564590-15-000886-index.html	Edgar Link	pending
0001564590-15-000886.txt	Edgar Link	pending
0001564590-15-000886-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g201502241835566685653.jpg	Edgar Link	pending
g201502241835567315654.jpg	Edgar Link	pending
g201502241835568095655.jpg	Edgar Link	pending
g201502241835568245656.jpg	Edgar Link	pending
g201502241835568565657.jpg	Edgar Link	pending
g201502241835569345658.jpg	Edgar Link	pending
g201502241835571845659.jpg	Edgar Link	pending
g201502241835572935660.jpg	Edgar Link	pending
g201502241835573095661.jpg	Edgar Link	pending
g201502241835574025662.jpg	Edgar Link	pending
g201502241835575435663.jpg	Edgar Link	pending
g201502241836055125664.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tndm-10k_20141231.htm	Edgar Link	pending
tndm-20141231.xml	Edgar Link	completed
tndm-20141231.xsd	Edgar Link	pending
tndm-20141231_cal.xml	Edgar Link	unprocessable
tndm-20141231_def.xml	Edgar Link	unprocessable
tndm-20141231_lab.xml	Edgar Link	unprocessable
tndm-20141231_pre.xml	Edgar Link	unprocessable
tndm-ex1025_201412311179.htm	Edgar Link	pending
tndm-ex231_20141231279.htm	Edgar Link	pending
tndm-ex311_201412316.htm	Edgar Link	pending
tndm-ex312_201412317.htm	Edgar Link	pending
tndm-ex321_201412318.htm	Edgar Link	pending
tndm-ex322_201412319.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNDM
TANDEM DIABETES CARE INC Stock $tndm

2015 Q1 Form 10-K Financial Statement

#000156459015000886 Filed on February 24, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNDM TANDEM DIABETES CARE INC Stock $tndm

2015 Q1 Form 10-K Financial Statement

#000156459015000886 Filed on February 24, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNDM
TANDEM DIABETES CARE INC Stock $tndm